Drug Profile
Delamanid - Otsuka Pharmaceutical
Alternative Names: 6-nitro-2,3-dihydroimidazol - Otsuka Pharmaceutical; Deltyba; OPC-67683Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Otsuka Pharmaceutical
- Developer Ewopharma; Otsuka Pharmaceutical; R-Pharm; Viatris Inc
- Class 2 ring heterocyclic compounds; Antituberculars; Nitroimidazoles; Oxazoles; Phenyl ethers; Piperidines; Small molecules
- Mechanism of Action Cell wall inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Tuberculosis
Most Recent Events
- 13 Jun 2022 Otsuka Pharmaceutical in collaboration with Bill and Melinda Gates Foundation completes a phase I/II trial for Tuberculosis (Combination therapy) in South Africa (PO) (NCT03678688)
- 22 Nov 2021 Otsuka Pharmaceuticals terminates a phase II trial in pulmonary sputum culture-positive MDR-Tuberculosis in Latvia and Lithuania
- 07 Oct 2021 Registered for Tuberculosis (Combination therapy, In children, Treatment-resistant) in European Union (PO)